PT2794597T - Derivados de piridinona e pirimidinona como inibidores do fator xia - Google Patents

Derivados de piridinona e pirimidinona como inibidores do fator xia

Info

Publication number
PT2794597T
PT2794597T PT128134236T PT12813423T PT2794597T PT 2794597 T PT2794597 T PT 2794597T PT 128134236 T PT128134236 T PT 128134236T PT 12813423 T PT12813423 T PT 12813423T PT 2794597 T PT2794597 T PT 2794597T
Authority
PT
Portugal
Prior art keywords
pyridinone
factor xia
xia inhibitors
pyrimidinone derivatives
pyrimidinone
Prior art date
Application number
PT128134236T
Other languages
English (en)
Portuguese (pt)
Inventor
Kondo Takashi
Yarnold Chris
Flanagan Stuart
Courtney Steve
Brace Gareth
Barker John
Ichihara Osamu
Gadouleau Elise
Richardson Anthony
Imagawa Akira
Nakatani Shingo
Suzuki Ryo
Kouyama Sho
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1122139.7A external-priority patent/GB2497806A/en
Priority claimed from GB201217290A external-priority patent/GB201217290D0/en
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of PT2794597T publication Critical patent/PT2794597T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT128134236T 2011-12-21 2012-12-20 Derivados de piridinona e pirimidinona como inibidores do fator xia PT2794597T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1122139.7A GB2497806A (en) 2011-12-21 2011-12-21 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
GB201217290A GB201217290D0 (en) 2012-09-27 2012-09-27 Compounds

Publications (1)

Publication Number Publication Date
PT2794597T true PT2794597T (pt) 2018-01-16

Family

ID=47553259

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128134236T PT2794597T (pt) 2011-12-21 2012-12-20 Derivados de piridinona e pirimidinona como inibidores do fator xia

Country Status (22)

Country Link
US (2) US9732085B2 (cg-RX-API-DMAC7.html)
EP (2) EP3290413B9 (cg-RX-API-DMAC7.html)
JP (2) JP6137193B2 (cg-RX-API-DMAC7.html)
KR (1) KR102011534B1 (cg-RX-API-DMAC7.html)
CN (1) CN104136431B (cg-RX-API-DMAC7.html)
AU (1) AU2012356374B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014015669B1 (cg-RX-API-DMAC7.html)
CA (1) CA2859604C (cg-RX-API-DMAC7.html)
DK (1) DK2794597T3 (cg-RX-API-DMAC7.html)
ES (2) ES2765891T3 (cg-RX-API-DMAC7.html)
HU (1) HUE036010T2 (cg-RX-API-DMAC7.html)
IL (1) IL233154A (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04676A (cg-RX-API-DMAC7.html)
MX (1) MX351471B (cg-RX-API-DMAC7.html)
NO (1) NO2794597T3 (cg-RX-API-DMAC7.html)
PH (1) PH12014501365B1 (cg-RX-API-DMAC7.html)
PL (1) PL2794597T3 (cg-RX-API-DMAC7.html)
PT (1) PT2794597T (cg-RX-API-DMAC7.html)
RU (1) RU2630677C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201403402VA (cg-RX-API-DMAC7.html)
TW (1) TWI613199B (cg-RX-API-DMAC7.html)
WO (1) WO2013093484A1 (cg-RX-API-DMAC7.html)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI577665B (zh) 2010-02-11 2017-04-11 必治妥美雅史谷比公司 作為因子xia抑制劑之巨環類
US9062061B2 (en) * 2011-07-13 2015-06-23 Santen Pharmaceutical Co., Ltd. Compound having PARP inhibitory activity
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
RS56168B1 (sr) 2011-10-14 2017-11-30 Bristol Myers Squibb Co Supstituisana jedinjenja tetrahidroizohinolina kao inhibitori xia faktora
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
KR102011534B1 (ko) * 2011-12-21 2019-08-16 오노 야꾸힝 고교 가부시키가이샤 인자 XIa 억제제로서 피리디논 및 피리미디논 유도체
EP2793879A4 (en) * 2011-12-23 2015-07-01 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
TW201416362A (zh) 2012-07-19 2014-05-01 Dainippon Sumitomo Pharma Co 1-(環烷基羰基)脯胺酸衍生物
BR112015002081A2 (pt) 2012-08-03 2017-07-04 Bristol Myers Squibb Co di-hidropiridona p1 como inibidores de fator xia
US9376444B2 (en) 2012-08-03 2016-06-28 Bristol-Myers Squibb Company Dihydropyridone P1 as factor XIa inhibitors
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
AU2013329125B2 (en) 2012-10-12 2017-03-30 Bristol-Myers Squibb Company Crystalline forms of a factor XIa inhibitor
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
EP2978425B1 (en) * 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JP6410819B2 (ja) * 2013-07-23 2018-10-24 バイエル ファーマ アクチエンゲゼルシャフト 置換オキソピリジン誘導体および第XIa因子/血漿としてのその使用
WO2015063093A1 (de) * 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
NO2760821T3 (cg-RX-API-DMAC7.html) 2014-01-31 2018-03-10
SG10201908467RA (en) * 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
WO2015123093A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
WO2015123091A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
EP3138839B1 (en) * 2014-02-14 2020-10-28 Sichuan Haisco Pharmaceutical Co., Ltd. Pyridone or pyrimidone derivative, preparation method therefor and application thereof
EP3134408B1 (en) 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2016011940A1 (zh) * 2014-07-25 2016-01-28 江苏恒瑞医药股份有限公司 氮茚-酰胺类衍生物、其制备方法及其在医药上的应用
EP3180317B1 (en) 2014-07-28 2021-04-14 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
EP3189047B1 (en) 2014-09-04 2018-12-26 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
CN104311537B (zh) * 2014-09-19 2016-08-24 广东东阳光药业有限公司 含有嘧啶酮乙酰基取代基吡唑类化合物及其组合物及用途
WO2016046164A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2722423T3 (es) * 2014-09-24 2019-08-12 Bayer Pharma AG Derivados de oxopiridina sustituidos
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR102525392B1 (ko) 2014-12-10 2023-04-24 오노 야꾸힝 고교 가부시키가이샤 디히드로인돌리지논 유도체
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
RU2649141C2 (ru) * 2015-04-20 2018-03-30 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 3,4-диметил-6-(3-пиридил)-N-фенил-2-оксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий противогрибковое действие в отношении штамма Candida albicans
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
RU2653511C2 (ru) * 2015-07-29 2018-05-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 4-метил-n-2,4-диметилфенил-6-(3-фторфенил)-2-тиоксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий анальгетическое действие
US10336730B2 (en) 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors
CN106496249B (zh) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用
US10344039B2 (en) * 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
MX387515B (es) 2015-10-29 2025-03-18 Merck Sharp & Dohme Llc Inhibidores de factor xia.
JP6992284B2 (ja) * 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物
TW201808908A (zh) 2016-08-22 2018-03-16 美商默沙東藥廠 因子XIa抑制劑
HUE057289T2 (hu) 2016-08-31 2022-05-28 Jiangsu Hengrui Medicine Co Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása
DE202017006776U1 (de) 2016-10-07 2018-05-16 Mitsubishi Hitec Paper Europe Gmbh Wärmeempfindliches Aufzeichnungsmaterial
EP3305538A1 (de) 2016-10-07 2018-04-11 Mitsubishi HiTec Paper Europe GmbH Wärmeempfindliches aufzeichnungsmaterial
CN106950319B (zh) * 2017-04-20 2019-08-30 西安科技大学 一种检测特鲁曲班光学异构体含量的方法
CN109507345B (zh) * 2017-09-15 2022-08-05 万特制药(海南)有限公司 重酒石酸卡巴拉汀中间体及其杂质的分离测定方法
UA126251C2 (uk) * 2018-02-27 2022-09-07 Джянгсу Хенгруй Медісін Ко., Лтд. Кристалічна форма похідної оксопіколінаміду та спосіб її отримання
EP3822264A4 (en) 2018-07-02 2021-11-10 Jiangsu Hengrui Medicine Co., Ltd. CRYSTALLINE FORMS OF AN OXYPYRIDINE AMIDE DERIVATIVE AND THEIR PREPARATION PROCESS
TWI825144B (zh) * 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
WO2020094156A1 (zh) * 2018-11-11 2020-05-14 上海海雁医药科技有限公司 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途
SG11202105697SA (en) * 2018-11-30 2021-06-29 Ono Pharmaceutical Co Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one
CN109836360B (zh) * 2019-03-19 2021-08-13 南京恩泰医药科技有限公司 一种甲苯磺酸依度沙班中间体的制备方法及中间体化合物
CN112028877B (zh) * 2019-06-04 2021-11-26 江西济民可信集团有限公司 烷氧吡啶酮化合物及其制备方法和用途
AU2020301451B2 (en) * 2019-06-28 2023-02-16 Jiangxi Jemincare Group Co., Ltd Tricyclic compound, preparation method therefor and use thereof
JP7450024B2 (ja) * 2019-09-27 2024-03-14 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド FXIa阻害剤及びその調製方法と医薬用途
CN112778277B (zh) * 2019-11-11 2024-04-02 江西济民可信集团有限公司 环酮并吡啶酮联杂芳环化合物及其制备方法和用途
WO2022018156A1 (en) * 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
JP2024125436A (ja) * 2021-07-20 2024-09-19 小野薬品工業株式会社 イミダゾール化合物の製造方法
US20230097157A1 (en) * 2021-07-22 2023-03-30 Janssen Pharmaceutica Nv Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
CN113735770B (zh) * 2021-09-30 2023-06-06 四川大学 一种铑催化的4-苯基噁二唑酮与碳酸亚乙烯酯合成1-氨基异喹啉骨架的方法
WO2023179624A1 (zh) * 2022-03-21 2023-09-28 上海济煜医药科技有限公司 三并环类化合物制备方法及其中间体
CN119677737A (zh) 2022-04-22 2025-03-21 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
CN116283908A (zh) * 2023-03-10 2023-06-23 合肥工业大学 一种n-芳香甲基吡啶酮类衍生物及其制备方法与应用
CN118406037B (zh) * 2024-06-25 2025-02-25 四川师范大学 一种三氮唑类衍生物及其制备方法和用途
CN118894814B (zh) * 2024-07-15 2025-09-12 上海康鹏科技股份有限公司 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1,2,3-三唑的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0042675A1 (en) 1980-06-20 1981-12-30 Norton Company Method of mounting a grinding wheel on a spindle
EP0221588A3 (en) 1982-05-18 1988-09-21 University Of Florida Brain-specific drug delivery
CA1241120A (en) 1985-10-01 1988-08-23 Sami A. Aly Alternate mark inversion (ami) receiver
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
DE4221583A1 (de) * 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
DE4407488A1 (de) * 1994-03-07 1995-09-14 Bayer Ag Verwendung von Biphenyl- und Pyridylmethylpyridonen
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 4-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
BRPI0518126A (pt) 2004-10-15 2008-10-28 Astrazeneca Ab composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição
ES2380632T3 (es) 2004-11-24 2012-05-17 Vertex Pharmceuticals Incorporated Derivados de ácido3-(2-(3-ACILAMINO-2-OXO-2H-PIRIDIN)-ACETILAMINO)-4-OXO-PENTANOICO y su uso como inhibidores de caspasas
AR056682A1 (es) 2005-07-29 2007-10-17 Kalypsys Inc COMPUESTOS MULTICíCLICOS DERIVADOS DE LA SULFONAMIDA COMO INHIBIDORES DE LA HISTONA DESACETILASA Y COMPOSICIoN FARMACÉUTICA
KR20080087817A (ko) 2005-12-14 2008-10-01 브리스톨-마이어스 스큅 컴퍼니 인자 xia 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체
CN101341129B (zh) * 2005-12-14 2011-12-14 布里斯托尔-迈尔斯斯奎布公司 作为因子xia抑制剂的芳基丙酰胺,芳基丙烯酰胺,芳基丙炔酰胺,或芳基甲基脲类似物
EP2074117A2 (en) * 2006-11-24 2009-07-01 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
EP2102189B1 (en) * 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
MX2010006379A (es) 2007-12-11 2010-09-07 Schering Corp Moduladores de la secretasa gamma.
CN102026996B (zh) * 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
BRPI1008473A2 (pt) 2009-02-06 2019-04-02 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. compostos heterocíclicos bicíclicos substituídos como moduladores de gama secretase
CA2813911A1 (en) 2010-10-07 2012-04-12 Takeda Pharmaceutical Company Limited 1,4-oxazepane derivatives
KR102011534B1 (ko) * 2011-12-21 2019-08-16 오노 야꾸힝 고교 가부시키가이샤 인자 XIa 억제제로서 피리디논 및 피리미디논 유도체

Also Published As

Publication number Publication date
US20150152112A1 (en) 2015-06-04
ES2765891T3 (es) 2020-06-11
US20170305917A1 (en) 2017-10-26
CN104136431B (zh) 2017-03-15
US10717738B2 (en) 2020-07-21
DK2794597T3 (en) 2018-01-15
AU2012356374A8 (en) 2014-08-07
JP6137193B2 (ja) 2017-05-31
ES2655669T3 (es) 2018-02-21
IN2014CN04676A (cg-RX-API-DMAC7.html) 2015-09-18
JP2015500868A (ja) 2015-01-08
CA2859604C (en) 2019-12-17
IL233154A0 (en) 2014-08-03
AU2012356374A1 (en) 2014-07-10
RU2630677C2 (ru) 2017-09-12
EP2794597A1 (en) 2014-10-29
RU2014129797A (ru) 2016-02-10
HK1198386A1 (en) 2015-04-17
NO2794597T3 (cg-RX-API-DMAC7.html) 2018-04-14
IL233154A (en) 2016-12-29
AU2012356374B2 (en) 2017-06-22
PH12014501365A1 (en) 2014-09-22
TW201339157A (zh) 2013-10-01
NZ626176A (en) 2015-09-25
MX351471B (es) 2017-10-17
WO2013093484A1 (en) 2013-06-27
PH12014501365B1 (en) 2014-09-22
HUE036010T2 (hu) 2018-06-28
CN104136431A (zh) 2014-11-05
US9732085B2 (en) 2017-08-15
EP3290413A1 (en) 2018-03-07
KR20140103286A (ko) 2014-08-26
EP3290413B9 (en) 2020-04-29
JP6447660B2 (ja) 2019-01-09
BR112014015669A8 (pt) 2017-07-04
EP3290413B1 (en) 2019-11-13
JP2017160239A (ja) 2017-09-14
PL2794597T3 (pl) 2018-03-30
EP2794597B1 (en) 2017-11-15
BR112014015669B1 (pt) 2021-10-13
BR112014015669A2 (pt) 2017-06-13
CA2859604A1 (en) 2013-06-27
SG11201403402VA (en) 2015-01-29
TWI613199B (zh) 2018-02-01
MX2014007269A (es) 2014-07-22
KR102011534B1 (ko) 2019-08-16

Similar Documents

Publication Publication Date Title
HUE036010T2 (hu) Piridinon és pirimidinon származékok mint XIA faktor inhibitorok
IL236036A0 (en) Pyridinone and pyridizinone derivatives
EP2703401A4 (en) PYRIDINE DERIVATIVE AND BACE-1 HEMMER THEREOF
IL237011A0 (en) Dihydropyridone p1 as factor xia inhibitors
SMT201700003T1 (it) DlIDROPIRIDONI COME INIBITORI DEL FATTORE XIA
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
ZA201405486B (en) Pyridone derivatives
SG11201400484RA (en) Novel heterocyclic derivatives and their uses
ZA201500917B (en) Pyrimidine pyrazolyl derivatives
ZA201401434B (en) Heterocyclic compounds and uses thereof
IL230536A0 (en) Heterocyclic compounds and their uses
EP2678016A4 (en) HETEROCYCLIC COMPOUNDS AND USES THEREOF
SG11201402409UA (en) Substituted pyridine derivatives as fabi inhibitors
ZA201307476B (en) New pyridazinone and pyridone compounds
EP2782571A4 (en) HETEROCYCLIC COMPOUNDS AND USES THEREOF